文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.

作者信息

Ten Haaf Kevin, Jeon Jihyoun, Tammemägi Martin C, Han Summer S, Kong Chung Yin, Plevritis Sylvia K, Feuer Eric J, de Koning Harry J, Steyerberg Ewout W, Meza Rafael

机构信息

Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.

Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States of America.

出版信息

PLoS Med. 2017 Apr 4;14(4):e1002277. doi: 10.1371/journal.pmed.1002277. eCollection 2017 Apr.


DOI:10.1371/journal.pmed.1002277
PMID:28376113
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5380315/
Abstract

BACKGROUND: Selection of candidates for lung cancer screening based on individual risk has been proposed as an alternative to criteria based on age and cumulative smoking exposure (pack-years). Nine previously established risk models were assessed for their ability to identify those most likely to develop or die from lung cancer. All models considered age and various aspects of smoking exposure (smoking status, smoking duration, cigarettes per day, pack-years smoked, time since smoking cessation) as risk predictors. In addition, some models considered factors such as gender, race, ethnicity, education, body mass index, chronic obstructive pulmonary disease, emphysema, personal history of cancer, personal history of pneumonia, and family history of lung cancer. METHODS AND FINDINGS: Retrospective analyses were performed on 53,452 National Lung Screening Trial (NLST) participants (1,925 lung cancer cases and 884 lung cancer deaths) and 80,672 Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) ever-smoking participants (1,463 lung cancer cases and 915 lung cancer deaths). Six-year lung cancer incidence and mortality risk predictions were assessed for (1) calibration (graphically) by comparing the agreement between the predicted and the observed risks, (2) discrimination (area under the receiver operating characteristic curve [AUC]) between individuals with and without lung cancer (death), and (3) clinical usefulness (net benefit in decision curve analysis) by identifying risk thresholds at which applying risk-based eligibility would improve lung cancer screening efficacy. To further assess performance, risk model sensitivities and specificities in the PLCO were compared to those based on the NLST eligibility criteria. Calibration was satisfactory, but discrimination ranged widely (AUCs from 0.61 to 0.81). The models outperformed the NLST eligibility criteria over a substantial range of risk thresholds in decision curve analysis, with a higher sensitivity for all models and a slightly higher specificity for some models. The PLCOm2012, Bach, and Two-Stage Clonal Expansion incidence models had the best overall performance, with AUCs >0.68 in the NLST and >0.77 in the PLCO. These three models had the highest sensitivity and specificity for predicting 6-y lung cancer incidence in the PLCO chest radiography arm, with sensitivities >79.8% and specificities >62.3%. In contrast, the NLST eligibility criteria yielded a sensitivity of 71.4% and a specificity of 62.2%. Limitations of this study include the lack of identification of optimal risk thresholds, as this requires additional information on the long-term benefits (e.g., life-years gained and mortality reduction) and harms (e.g., overdiagnosis) of risk-based screening strategies using these models. In addition, information on some predictor variables included in the risk prediction models was not available. CONCLUSIONS: Selection of individuals for lung cancer screening using individual risk is superior to selection criteria based on age and pack-years alone. The benefits, harms, and feasibility of implementing lung cancer screening policies based on risk prediction models should be assessed and compared with those of current recommendations.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168e/5380315/f0fa6b2356fd/pmed.1002277.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168e/5380315/eb27b4833999/pmed.1002277.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168e/5380315/83de34d54799/pmed.1002277.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168e/5380315/6b77eed37cb3/pmed.1002277.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168e/5380315/e9dc5a9d9903/pmed.1002277.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168e/5380315/a8cf86172062/pmed.1002277.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168e/5380315/f0fa6b2356fd/pmed.1002277.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168e/5380315/eb27b4833999/pmed.1002277.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168e/5380315/83de34d54799/pmed.1002277.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168e/5380315/6b77eed37cb3/pmed.1002277.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168e/5380315/e9dc5a9d9903/pmed.1002277.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168e/5380315/a8cf86172062/pmed.1002277.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168e/5380315/f0fa6b2356fd/pmed.1002277.g006.jpg

相似文献

[1]
Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.

PLoS Med. 2017-4-4

[2]
Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study.

PLoS Med. 2023-10

[3]
OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.

EBioMedicine. 2023-2

[4]
Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.

JAMA. 2016-6-7

[5]
Selection criteria for lung-cancer screening.

N Engl J Med. 2013-2-21

[6]
Selecting High-Risk Individuals for Lung Cancer Screening: A Prospective Evaluation of Existing Risk Models and Eligibility Criteria in the German EPIC Cohort.

Cancer Prev Res (Phila). 2015-9

[7]
Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.

Ann Intern Med. 2020-11-3

[8]
Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.

Lancet Oncol. 2017-10-18

[9]
Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO risk prediction tool.

Int J Cancer. 2017-4-21

[10]
Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.

PLoS Med. 2014-12-2

引用本文的文献

[1]
Te Oranga Pūkahukahu research programme: intentional steps towards a national equity-focused lung cancer screening programme in Aotearoa New Zealand.

J R Soc N Z. 2025-2-12

[2]
A blood test-based machine learning model for predicting lung cancer risk.

Front Med (Lausanne). 2025-6-17

[3]
Polygenic Risk Score Is Associated with Developing and Dying from Lung Cancer in the National Lung Screening Trial.

J Clin Med. 2025-4-30

[4]
Impact of Low-Dose Computed Tomography Findings on Cigarette Smoking Cessation Among High-Risk Adults Participating in Lung Cancer Screening.

Nicotine Tob Res. 2025-7-22

[5]
Future risk projection to engage 'near-miss' individuals in lung cancer screening eligibility: an analysis of ILST data.

Thorax. 2025-7-15

[6]
Patina of precision: risk models for lung cancer screening eligibility.

BMJ Oncol. 2025-1-29

[7]
Navigating the risks: Stakeholder views on risk-based cervical cancer screening.

PLoS One. 2025-3-5

[8]
Predictive performance of risk prediction models for lung cancer incidence in Western and Asian countries: a systematic review and meta-analysis.

Sci Rep. 2025-3-4

[9]
Head-to-head comparisons of risk discrimination by questionnaire-based lung cancer risk prediction models: a systematic review and meta-analysis.

EClinicalMedicine. 2025-1-30

[10]
Carnitine palmitoyltransferase 1C promotes EMT-associated cisplatin resistance in non-small cell lung cancer cells.

Cancer Biol Med. 2025-2-4

本文引用的文献

[1]
Lung cancer screening: latest developments and unanswered questions.

Lancet Respir Med. 2016-9

[2]
Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.

JAMA. 2016-6-7

[3]
Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial.

Lancet Oncol. 2016-5

[4]
A calibration hierarchy for risk models was defined: from utopia to empirical data.

J Clin Epidemiol. 2016-6

[5]
Sample size considerations for the external validation of a multivariable prognostic model: a resampling study.

Stat Med. 2016-1-30

[6]
Evaluation of a Personalized, Web-Based Decision Aid for Lung Cancer Screening.

Am J Prev Med. 2015-12

[7]
Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

J Thorac Oncol. 2015-9

[8]
Selecting High-Risk Individuals for Lung Cancer Screening: A Prospective Evaluation of Existing Risk Models and Eligibility Criteria in the German EPIC Cohort.

Cancer Prev Res (Phila). 2015-9

[9]
Overdiagnosis in lung cancer screening: why modelling is essential.

J Epidemiol Community Health. 2015-11

[10]
Imputation of systematically missing predictors in an individual participant data meta-analysis: a generalized approach using MICE.

Stat Med. 2015-5-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索